Legislative Catalyst: NOPAIN for Veterans Act
The NOPAIN for Veterans Act is a bipartisan bill introduced in late 2024 to expand access to non-opioid pain management therapies for veterans. It builds on the earlier NOPAIN Act of 2022, which ensured Medicare coverage for such treatments. This new legislation:
Requires the VA to include FDA-cleared non-opioid pain therapies in its National Formulary if they’re already covered by Medicare2.
Mandates reimbursement for these therapies, meaning veterans won’t have to pay out-of-pocket.
Ensures prescribing access, allowing VA doctors to recommend these treatments directly.
This is a major shift in how pain is managed within the VA system—moving away from opioids and toward safer, non-addictive alternatives.
FDA-Cleared Solutions: ActiPatch & RecoveryRx
BioElectronics Corporation (BIEL) produces ActiPatch and RecoveryRx, wearable devices that use pulsed electromagnetic field (PEMF) therapy to reduce pain and inflammation. These devices:
Are FDA-cleared for treating musculoskeletal pain and post-operative recovery.
Have shown effectiveness in reducing reliance on opioids.
Are non-invasive, drug-free, and safe for long-term use.
With the NOPAIN for Veterans Act, these products become eligible for VA formulary inclusion, meaning they can be:
Prescribed by VA clinicians
Reimbursed directly by the VA
Distributed to veterans nationwide
Why This Is Game-Changing for BIEL
This legislation aligns perfectly with BIEL’s mission to provide safe, accessible pain relief. The Act:
Opens the door to massive adoption within the VA system.
Creates a new revenue stream through government reimbursement.
Validates BIEL’s technology as part of a national strategy to combat opioid addiction.
In short, it’s a legislative green light for BIEL to scale its impact—both medically and commercially.
The NOPAIN for Veterans Act is a bipartisan bill introduced in late 2024 to expand access to non-opioid pain management therapies for veterans. It builds on the earlier NOPAIN Act of 2022, which ensured Medicare coverage for such treatments. This new legislation:
Requires the VA to include FDA-cleared non-opioid pain therapies in its National Formulary if they’re already covered by Medicare2.
Mandates reimbursement for these therapies, meaning veterans won’t have to pay out-of-pocket.
Ensures prescribing access, allowing VA doctors to recommend these treatments directly.
This is a major shift in how pain is managed within the VA system—moving away from opioids and toward safer, non-addictive alternatives.
FDA-Cleared Solutions: ActiPatch & RecoveryRx
BioElectronics Corporation (BIEL) produces ActiPatch and RecoveryRx, wearable devices that use pulsed electromagnetic field (PEMF) therapy to reduce pain and inflammation. These devices:
Are FDA-cleared for treating musculoskeletal pain and post-operative recovery.
Have shown effectiveness in reducing reliance on opioids.
Are non-invasive, drug-free, and safe for long-term use.
With the NOPAIN for Veterans Act, these products become eligible for VA formulary inclusion, meaning they can be:
Prescribed by VA clinicians
Reimbursed directly by the VA
Distributed to veterans nationwide
Why This Is Game-Changing for BIEL
This legislation aligns perfectly with BIEL’s mission to provide safe, accessible pain relief. The Act:
Opens the door to massive adoption within the VA system.
Creates a new revenue stream through government reimbursement.
Validates BIEL’s technology as part of a national strategy to combat opioid addiction.
In short, it’s a legislative green light for BIEL to scale its impact—both medically and commercially.
1
